ValuEngine Downgrades Cleveland BioLabs, Inc. (CBLI) to Sell
Cleveland BioLabs, Inc. (NASDAQ:CBLI) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.
Shares of Cleveland BioLabs (CBLI) traded down 8.81% during mid-day trading on Thursday, reaching $3.00. 135,456 shares of the company traded hands. The stock’s 50-day moving average is $3.52 and its 200-day moving average is $2.37. Cleveland BioLabs has a 52 week low of $1.22 and a 52 week high of $5.55. The company’s market capitalization is $33.84 million.
Cleveland BioLabs (NASDAQ:CBLI) last announced its earnings results on Monday, May 15th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $0.58 million for the quarter. Cleveland BioLabs had a negative return on equity of 28.45% and a negative net margin of 111.40%. On average, equities analysts predict that Cleveland BioLabs will post ($0.16) EPS for the current fiscal year.
About Cleveland BioLabs
Cleveland BioLabs, Inc (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with MarketBeat.com's FREE daily email newsletter.